Biopharma’s Winners and Losers of 2025 – Endpoints News recap
Endpoints News runs an annual “winners and losers” list highlighting which biopharma companies, executives, and themes had notably positive or negative years.13
For 2025, the Endpoints newsroom spent several weeks reviewing biopharma’s biggest developments to select that year’s winners and losers, then discussed them on a dedicated Post‑Hoc Live segment titled along the lines of “Biopharma’s Winners and Losers of 2025.”13
The 2025 list is presented as an editorial, qualitative assessment, not a quantitative ranking, and is framed as a year‑in‑review of who was “up” and who was “down” across the industry.13
Endpoints promoted the feature and livestream in advance, noting that *“The Endpoints Winners and Losers list is back — and we’re bringing it to Post‑Hoc … Coming tomorrow at noon:
Our 2025 winners and losers list — on Post‑Hoc Live.”*3
The full, specific breakdown of which companies or individuals were on the ‘up’ vs. ‘down’ side in 2025 is paywalled / embedded in the Post‑Hoc Live content and is not fully accessible from open snippets, so only high‑level characterization of the feature is available from public search results.13